Growth factor signaling in metastasis: Current understanding and future opportunities

Cancer and Metastasis Reviews

Volumn 31, Issue 3-4, 2012, Pages 479-491

  Lowery, Frank J ^a   Yu, Dihua ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

c MET; EGFR; Growth factor signaling; HER2; In vivo models; Metastasis; Targeted therapies; TGF ; VEGF

Indexed keywords

BEVACIZUMAB; CABOZANTINIB; CANCER ANTIBODY; CETUXIMAB; CISPLATIN; CRIZOTINIB; DENOSUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; GEFITINIB; GELATINASE B; GROWTH FACTOR; K RAS PROTEIN; LAPATINIB; OSTEOPONTIN; PACLITAXEL; PAZOPANIB; RILOTUMUMAB; SCATTER FACTOR RECEPTOR; SMAD3 PROTEIN; TIVANTINIB; TIVOZANIB; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CARCINOMA CELL; CASTRATION RESISTANT PROSTATE CANCER; COLORECTAL CANCER; DRUG APPROVAL; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; IN VIVO STUDY; KIDNEY CARCINOMA; LUNG ENDOTHELIUM; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR BINDING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; SRC HOMOLOGY DOMAIN; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867999300     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-012-9380-x     Document Type: Article

References (153)

1. Hanahan, D.; & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646-74.
2. Paget, S. (1989). The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Reviews, 8(2), 98-101.
3. Talmadge, J. E.; Wolman, S. R.; & Fidler, I. J. (1982). Evidence for the clonal origin of spontaneous metastases. Science, 217(4557), 361-363.
4. Yang, J.; et al. (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell, 117(7), 927-939.
5. Folkman, J. (2002). Role of angiogenesis in tumor growth and metastasis. Seminars in Oncology, 29(6 Suppl 16), 15-18.
6. Croci, D. O.; & Salatino M. (2011). Tumor immune escape mechanisms that operate during metastasis. Current Pharmaceutical Biotechnology, 12(11), 1923-1936.
7. Linggi, B.; & Carpenter, G. (2006). ErbB receptors: New insights on mechanisms and biology. Trends in Cell Biology, 16(12), 649-656.
8. Werner, M. H.; et al. (1988). Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines. Acta Neuropathologica, 77(2), 196-201.
9. Velu, T. J.; et al. (1987). Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science, 238(4832), 1408-1410.
10. Di Fiore, P. P.; et al. (1987). Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell, 51(6), 1063-1070.
11. Sainsbury, J. R.; et al. (1987). Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet, 1(8547), 1398-1402.
12. Wong, A. J.; et al. (1987). Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proceedings of the National Academy of Sciences of the United States of America, 84(19), 6899-6903.
13. Veale, D.; et al. (1987). Epidermal growth factor receptors in non-small cell lung cancer. British Journal of Cancer, 55(5), 513-516.
14. Lu, Z.; et al. (2001). Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Molecular and Cellular Biology, 21(12), 4016-4031.
15. Lu, Z.; et al. (2003). Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell, 4(6), 499-515.
16. Onodera, Y.; et al. (2005). Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities. EMBO Journal, 24(5), 963-973.
17. Huang, M.; et al. (2012). EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation. Oncogene, 31, 2783-2793.
18. Ueno, Y.; et al. (2008). Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. International Journal of Cancer, 123(2), 340-347.
19. Minn, A. J.; et al. (2005). Genes that mediate breast cancer metastasis to lung. Nature, 436(7050), 518-524.
20. Bos, P. D.; et al. (2009). Genes that mediate breast cancer metastasis to the brain. Nature, 459(7249), 1005-1009.
21. Guo, Z.; et al. (2007). The synergistic effects of CXCR4 and EGFR on promoting EGF-mediated metastasis in ovarian cancer cells. Colloids and Surfaces. B, Biointerfaces, 60(1), 1-6.
22. Kajiyama, H.; et al. (2008). Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. International Journal of Cancer, 122(1), 91-99.
23. Holmes, W. E.; et al. (1992). Identification of heregulin, a specific activator of p185erbB2. Science, 256(5060), 1205-1210.
24. Spivak-Kroizman, T.; et al. (1992). Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses. Journal of Biological Chemistry, 267(12), 8056-8063.
25. Hendriks, B. S.; et al. (2003). Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: Distribution of homo- and heterodimers depends on relative HER2 levels. Journal of Biological Chemistry, 278(26), 23343-23351.
26. Sternberg, M. J.; & Gullick, W. J. (1989). Neu receptor dimerization. Nature, 339(6226), 587.
27. Varley, J. M.; et al. (1987). Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene, 1(4), 423-430.
28. van de Vijver, M.; et al. (1987). Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Molecular and Cellular Biology, 7(5), 2019-2023.
29. Guerin, M.; et al. (1988). Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: Correlation with poor prognosis. Oncogene Research, 3(1), 21-31.
30. Makar, A. P.; et al. (1990). Neu (C-erbB-2) oncogene in breast cancer and its possible association with the risk of distant metastases. A retrospective study and review of literature. Acta Oncologica, 29(7), 931-934.
31. Yu, D. H.; & Hung, M. C. (1991). Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene, 6(11), 1991-1996.
32. Yu, D.; et al. (1992). Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. Oncogene, 7(11), 2263-2270.
33. Yu, D.; et al. (1994). c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Research, 54(12), 3260-3266.
34. Zhau, H. Y.; et al. (1996). Transfected neu oncogene induces human prostate cancer metastasis. Prostate, 28(2), 73-83.
35. Moody, S. E.; et al. (2002). Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell, 2(6), 451-461.
36. Hsu, M. C.; Chang, H. C.; & Hung, W. C. (2006). HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion. Journal of Biological Chemistry, 281(8), 4718-4725.
37. Pedersen, K.; et al. (2009). A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Molecular and Cellular Biology, 29(12), 3319-3331.
38. Klos, K. S.; et al. (2006). ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Research, 66(4), 2028-2037.
39. Li, Y. M.; et al. (2004). Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell, 6(5), 459-469.
40. Giordano, S.; et al. (1989). Tyrosine kinase receptor indistinguishable from the c-met protein. Nature, 339(6220), 155-156.
41. Gardo, S. (1977). The use of limovanil in pregnancy. Orvosi Hetilap, 118(11), 660.
42. Graziani, A.; et al. (1991). The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. Journal of Biological Chemistry, 266(33), 22087-22090.
43. Gentile, A.; Trusolino, L.; & Comoglio, P. M. (2008). The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Reviews, 27(1), 85-94.
44. Rong, S.; et al. (1994). Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proceedings of the National Academy of Sciences of the United States of America, 91(11), 4731-4735.
45. Webb, C. P.; et al. (1998). Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene, 17(16), 2019-2025.
46. Furge, K. A.; et al. (2001). Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America, 98(19), 10722-10727.
47. Navab, R.; et al. (2009). Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia, 11(12), 1292-1300.
48. Giordano, S.; et al. (1997). A point mutation in the MET oncogene abrogates metastasis without affecting transformation. Proceedings of the National Academy of Sciences of the United States of America, 94(25), 13868-13872.
49. Bardelli, A.; et al. (1999). Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. Oncogene, 18(5), 1139-1146.
50. Previdi, S.; et al. (2010). Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. European Journal of Cancer, 46(9), 1679-1691.
51. Previdi, S.; et al. (2011). Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. Molecular Cancer Therapeutics, 11(1), 214-223.
52. Dong, G.; et al. (2004). Metastatic squamous cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor. Oncogene, 23(37), 6199-6208.
53. Jeffers, M.; Rong, S.; & Vande Woude, G. F. (1996). Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Molecular and Cellular Biology, 16(3), 1115-1125.
54. Otsuka, T.; et al. (2000). Disassociation of met-mediated biological responses in vivo: The natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis. Molecular and Cellular Biology, 20(6), 2055-2065.
55. Yu, Y.; & Merlino, G. (2002). Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model. Cancer Research, 62(10), 2951-2956.
56. Massague, J. (1998). TGF-beta signal transduction. Annual Review of Biochemistry, 67, 753-791.
57. Meulmeester, E.; & Ten Dijke, P. (2011). The dynamic roles of TGF-beta in cancer. Journal of Pathology, 223(2), 205-218.
58. Kang, Y.; et al. (2005). Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proceedings of the National Academy of Sciences of the United States of America, 102(39), 13909-13914.
59. Deckers, M.; et al. (2006). The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Research, 66(4), 2202-2209.
60. Bandyopadhyay, A.; et al. (2006). Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Research, 66(13), 6714-6721.
61. Korpal, M.; et al. (2009). Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nature Medicine, 15(8), 960-966.
62. Ganapathy, V.; et al. (2010). Targeting the transforming growth factor-beta pathway inhibits human basal-like breast cancer metastasis. Molecular Cancer, 9, 122.
63. Biswas, S.; et al. (2011). Anti-transforming growth factor ss antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. PLoS One, 6(11), e27090.
64. Johnson, R. W.; et al. (2011). TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Research, 71(3), 822-831.
65. Petersen, M.; et al. (2009). Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis. Oncogene, 29(9), 1351-1361.
66. Kominsky, S. L.; et al. (2007). TGF-beta promotes the establishment of renal cell carcinoma bone metastasis. Journal of Bone and Mineral Research, 22(1), 37-44.
67. Kominsky, S. L.; et al. (2008). MMP-13 is over-expressed in renal cell carcinoma bone metastasis and is induced by TGF-beta1. Clinical & Experimental Metastasis, 25(8), 865-870.
68. Hoefer, M.; & Anderer, F. A. (1995). Anti-(transforming growth factor beta) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice. Cancer Immunology, Immunotherapy, 41(5), 302-308.
69. Zhang, C.; et al. (2009). Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brain. Cancer Research, 69(3), 828-835.
70. Pakala, S. B.; et al. (2011). TGF-beta1 signaling targets metastasis-associated protein 1, a new effector in epithelial cells. Oncogene, 30(19), 2230-2241.
71. Teraoka, H.; et al. (2001). Enhanced VEGF production and decreased immunogenicity induced by TGF-beta 1 promote liver metastasis of pancreatic cancer. British Journal of Cancer, 85(4), 612-617.
72. Teraoka, H.; et al. (2001). TGF-beta1 promotes liver metastasis of pancreatic cancer by modulating the capacity of cellular invasion. International Journal of Oncology, 19(4), 709-715.
73. Sawada, T.; et al. (2006). TGF-beta1 down-regulates ICAM-1 expression and enhances liver metastasis of pancreatic cancer. Advances in Medical Sciences, 51, 60-65.
74. Melisi, D.; et al. (2008). LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Molecular Cancer Therapeutics, 7(4), 829-840.
75. Weeks, B. H.; et al. (2001). Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis. Cancer Research, 61(20), 7435-7443.
76. Han, G.; et al. (2005). Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. The Journal of Clinical Investigation, 115(7), 1714-1723.
77. Ganapathy, A.; et al. (2010). TGF-beta inhibits metastasis in late stage human squamous cell carcinoma of the skin by a mechanism that does not involve Id1. Cancer Letters, 298(1), 107-118.
78. McEarchern, J. A.; et al. (2001). Invasion and metastasis of a mammary tumor involves TGF-beta signaling. International Journal of Cancer, 91(1), 76-82.
79. Siegel, P. M.; et al. (2003). Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proceedings of the National Academy of Sciences of the United States of America, 100(14), 8430-8435.
80. Moore, L. D.; et al. (2008). Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo. Clinical Cancer Research, 14(15), 4961-4970.
81. Bandyopadhyay, A.; et al. (1999). A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Research, 59(19), 5041-5046.
82. Tian, F.; et al. (2004). Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Research, 64(13), 4523-4530.
83. Forrester, E.; et al. (2005). Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Research, 65(6), 2296-2302.
84. + myeloid cells that promote metastasis. Cancer Cell, 13(1), 23-35.
85. Stearns, M. E.; et al. (1999). Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clinical Cancer Research, 5(3), 711-720.
86. Tu, W. H.; et al. (2003). The loss of TGF-beta signaling promotes prostate cancer metastasis. Neoplasia, 5(3), 267-277.
87. Folkman, J.; et al. (1971). Isolation of a tumor factor responsible for angiogenesis. The Journal of Experimental Medicine, 133(2), 275-288.
88. Senger, D. R.; et al. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 219(4587), 983-985.
89. Leung, D. W.; et al. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 246(4935), 1306-1309.
90. Kim, K. J.; et al. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature, 362(6423), 841-844.
91. Melnyk, O.; Shuman, M. A.; & Kim, K. J. (1996). Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Research, 56(4), 921-924.
92. Goldman, C. K.; et al. (1998). Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proceedings of the National Academy of Sciences of the United States of America, 95(15), 8795-8800.
93. Eriksson, A.; et al. (2002). Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell, 1(1), 99-108.
94. Sweeney, P.; et al. (2002). Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clinical Cancer Research, 8(8), 2714-2724.
95. Dai, J.; et al. (2009). Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene, 28(38), 3412-3422.
96. Dankort, D.; et al. (2001). Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: Implications for human breast cancer. Molecular and Cellular Biology, 21(5), 1540-1551.
97. Oshima, R. G.; et al. (2004). Angiogenic acceleration of Neu induced mammary tumor progression and metastasis. Cancer Research, 64(1), 169-179.
98. Laird, A. D.; et al. (2003). Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells. Molecular Cancer Therapeutics, 2(5), 461-469.
99. Chou, M. T.; Wang, J.; & Fujita, D. J. (2002). Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells. BMC Biochemistry, 3, 32.
100. Eliceiri, B. P.; et al. (1999). Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Molecular Cell, 4(6), 915-924.
101. Weis, S.; et al. (2004). Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. The Journal of Cell Biology, 167(2), 223-229.
102. Daenen, L. G.; et al. (2011). Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells. Cancer Research, 71(22), 6976-6985.
103. Hu, Z.; et al. (2009). A compact VEGF signature associated with distant metastases and poor outcomes. BMC Medicine, 7, 9.
104. Wei, D.; et al. (2003). Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene, 22(3), 319-329.
105. Xu, Q.; et al. (2005). Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene, 24(36), 5552-5560.
106. Verheul, H. M.; et al. (2007). Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clinical Cancer Research, 13(14), 4201-4208.
107. Kanayama, H.; et al. (1999). Expression of vascular endothelial growth factor by human renal cancer cells enhances angiogenesis of primary tumors and production of ascites but not metastasis to the lungs in nude mice. Clinical & Experimental Metastasis, 17(10), 831-840.
108. Rofstad, E. K.; & Halsor, E. F. (2000). Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Research, 60(17), 4932-4938.
109. Kienast, Y.; et al. (2009). Real-time imaging reveals the single steps of brain metastasis formation. Nature Medicine, 16(1), 116-122.
110. Atalay, G.; et al. (2003). Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Annals of Oncology, 14(9), 1346-1363.
111. Yonesaka, K.; et al. (2011). Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Science Translational Medicine, 3(99), 99ra86.
112. Maemondo, M.; et al. (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New England Journal of Medicine, 362(25), 2380-2388.
113. Jamal-Hanjani, M.; & Spicer, J. (2011). Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clinical Cancer Research, 18(4), 938-944.
114. Cristofanilli, M.; et al. (2010). Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clinical Cancer Research, 16(6), 1904-1914.
115. Takano, T.; et al. (2008). EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: A historical comparison of patients treated before and after gefitinib approval in Japan. Journal of Clinical Oncology, 26(34), 5589-5595.
116. Sequist, L. V.; et al. (2011). Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science Translational Medicine, 3(75), 75ra26.
117. Arteaga, C. L.; et al. (2011). Treatment of HER2-positive breast cancer: current status and future perspectives. Nature Reviews Clinical Oncology, 9(1), 16-32.
118. Vogel, C. L.; et al. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology, 20(3), 719-726.
119. Piccart-Gebhart, M. J.; et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. The New England Journal of Medicine, 353(16), 1659-1672.
120. Romond, E. H.; et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. The New England Journal of Medicine, 353(16), 1673-1684.
121. Park, Y. H.; et al. (2009). Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. British Journal of Cancer, 100(6), 894-900.
122. Zhang, S.; et al. (2011). Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nature Medicine, 17(4), 461-469.
123. Niculescu-Duvaz, I. (2010). Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer. Curr Opin Mol Ther, 12(3), 350-360.
124. Bowles, D. W.; Kessler, E. R.; & Jimeno, A. (2011). Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). Drugs Today (Barcelona, Spain), 47(11), 857-868.
125. ArQule, D. S. D. L. (2012). ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer. http://clinicaltrials.gov/ct2/show/NCT01244191. Accessed on 1 Mar 2012.
126. Pfizer, E. (2012). CREATE: Cross-tumoral Phase 2 With Crizotinib. http://clinicaltrials.gov/ct2/show/NCT01524926. Accessed on 1 Mar 2012.
127. Burgess, T.; et al. (2006). Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Research, 66(3), 1721-1729.
128. Ferrara, N. (2004). Vascular endothelial growth factor: Basic science and clinical progress. Endocrine Reviews, 25(4), 581-611.
129. Roche still sees peak Avastin sales 7 billion francs. Reuters, 2011.
130. Tanne, J. H. (2011). FDA cancels approval for bevacizumab in advanced breast cancer. BMJ, 343, d7684.
131. Burger, R. A.; et al. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. New England Journal of Medicine, 365(26), 2473-2483.
132. Reck, M.; et al. (2010). Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Annals of Oncology, 21(9), 1804-1809.
133. Dotan, E.; et al. (2012). A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. Journal of Gastrointestinal Cancer. doi: 10.1007/s12029-012-9368-3.
134. Thompson Coon, J.; et al. (2010). Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: A systematic review and economic evaluation. Health Technology Assessessment, 14(2), 1-184, iii-iv.
135. Koc, G.; Wang, X.; & Luo, Y. (2011). Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma. The Canadian Journal of Urology, 18(6), 5991-5997.
136. Inui, E. (2012). Market watch: upcoming market catalysts in Q1 2012. Nature Reviews Drug Discovery, 11(1), 10.
137. Conley, S. J.; et al. (2012). Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 109(8), 2784-2789.
138. Park, E. S.; et al. (2011). Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proceedings of the National Academy of Sciences of the United States of America, 108(42), 17456-17461.
139. Ooi, L. L.; et al. (2011). The bone remodeling environment is a factor in breast cancer bone metastasis. Bone, 48(1), 66-70.
140. Sims, N. A.; & Gooi, J. H. (2008). Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption. Seminars in Cell & Developmental Biology, 19(5), 444-451.
141. Sethi, N.; et al. (2011). Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell, 19(2), 192-205.
142. Lipton, A.; & Jun, S. (2008). RANKL inhibition in the treatment of bone metastases. Current Opinion in Supportive and Palliative Care, 2(3), 197-203.
143. Yang, J. C.; et al. (2010). Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model. Molecular Cancer Therapeutics, 9(6), 1629-1637.
144. Guo, A.; et al. (2008). Signaling networks assembled by oncogenic EGFR and c-Met. Proceedings of the National Academy of Sciences of the United States of America, 105(2), 692-697.
145. Ambros, V. (2001). microRNAs: Tiny regulators with great potential. Cell, 107(7), 823-826.
146. Bartel, D. P. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell, 116(2), 281-297.
147. Xu, B.; et al. (2012). MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. Prostate. doi: 10.1002/pros.22466.
148. Gong, C.; et al. (2011). Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. The Journal of Biological Chemistry, 286(21), 19127-19137.
149. Tsuruta, T.; et al. (2011). miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Research, 71(20), 6450-6462.
150. Turcatel, G.; et al. (2012). MIR-99a and MIR-99b modulate TGF-beta induced epithelial to mesenchymal plasticity in normal murine mammary gland cells. PLoS One, 7(1), e31032.
151. Yue, X.; et al. (2011). MicroRNA-205 functions as a tumor suppressor in human glioblastoma cells by targeting VEGF-A. Oncology Reports, 27(4), 1200-1206.
152. Santaris Pharma A/S (2010-2012). Multiple ascending dose study of miravirsen in treatment-naïve chronic hepatitis C subjects.
153. Garofalo, M.; et al. (2011). EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nature Medicine, 18(1), 74-82.